Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE AND OLMESARTAN MEDOXOMIL versus AVALIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE AND OLMESARTAN MEDOXOMIL versus AVALIDE.
AMLODIPINE AND OLMESARTAN MEDOXOMIL vs AVALIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, resulting in vasodilation and decreased aldosterone secretion.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Initial: 5 mg/20 mg orally once daily. Titrate after 1-2 weeks. Maximum: 10 mg/40 mg daily.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
None Documented
None Documented
Amlodipine: 30-50 hours (steady-state achieved after 7-8 days; permits once-daily dosing). Olmesartan: 10-15 hours.
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Amlodipine: ~60% renal (10% unchanged, 50% as metabolites), ~20-25% biliary/fecal. Olmesartan: ~35-50% renal (unchanged), ~50-65% biliary/fecal (unchanged).
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Category D/X
Category C
ARB
ARB and Thiazide Diuretic Combination